Iteos Therapeutics Inc. (ITOS)
NASDAQ (NMS) NASDAQ (NMS) Primary Summary
ITOS Chart
iTeos Therapeutics (ITOS) Upgraded to Buy: Here's What You Should Know
iTeos Therapeutics (ITOS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Wall Street Analysts See a 211.07% Upside in iTeos Therapeutics (ITOS): Can the Stock Really Move This High?
The consensus price target hints at a 211.1% upside potential for iTeos Therapeutics (ITOS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
iTeos Therapeutics: Decimated By Collateral Events, Good Chances Of Success Nevertheless
iTeos' lead molecule, Belrestotug, shows promising efficacy in trials despite setbacks in the anti-TIGIT space, with significant partnerships and a strong cash position. The stock has suffered due to failures of similar molecules from competitors, but iTeos' data remains positive, attracting major investments. Financially, iTeos has a solid runway with a market cap of $255mn and cash reserves nearly twice that, ensuring stability.
Iteos Therapeutics Inc. (ITOS) FAQ
What does "Delisted" mean?
What was the last recorded dividend?
How long did the company pay dividends?
Were there any stock splits?
What was the last known trading price?
Iteos Therapeutics Inc. Profile
| - Industry | - Sector | Michel Detheux CEO | NASDAQ (NMS) Exchange | 46565G104 CUSIP |
| US Country | 173 Employees | - Last Dividend | - Last Split | 24 Jul 2020 IPO Date |
Overview
Iteos Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immuno-oncology therapeutics aimed at improving the lives of patients with cancer. The company is at the forefront of developing therapies that engage the immune system to recognize and combat cancer cells more effectively. Founded in 2011 and based in Watertown, Massachusetts, Iteos Therapeutics has emerged as a key player in the oncology sector, leveraging cutting-edge science to advance its mission of delivering transformative cancer treatments.
Products and Services
Belrestotug (TIGIT antagonist): Belrestotug, the company's lead antibody product candidate, targets TIGIT (T-cell immunoreceptor with Ig and ITIM domains), an immune checkpoint axis that plays a crucial role in suppressing the immune response against cancer cells. Currently in Phase 1b clinical trials, belrestotug is designed to block the interaction between TIGIT and its ligands, thereby activating key components of the immune system such as dendritic cells, natural killer cells, and macrophages. This activation promotes antibody-dependent cellular cytotoxicity (ADCC) activity, which is crucial for the immune-mediated destruction of tumor cells.
Inupadenant (A2AR antagonist): A next-generation antagonist of the A2A receptor (A2AR), inupadenant is specifically developed to counteract the immunosuppression mediated by adenosine in the tumor microenvironment. By inhibiting the A2AR, inupadenant aims to restore the immune system's ability to fight cancer. This promising candidate is currently in Phase 1/2a clinical trials, focusing on its potential to overcome one of the key mechanisms by which tumors evade the immune response.
EOS-984 (ENT1 Inhibitor): EOS-984 represents Iteos Therapeutics’ venture into small molecule drug development, with a focus on equilibrative nucleoside transporter 1 (ENT1). ENT1 plays a significant role in the utilization of adenosine by cells, and this compound aims to inhibit its activity. By blocking ENT1, EOS-984 seeks to reduce the immunosuppressive activity of adenosine within the tumor environment, thereby restoring the proliferation and function of immune cells. Currently in Phase 1 clinical trials, EOS-984 is being investigated for its potential to revitalize immune responses in cancer patients by addressing a novel target in immuno-oncology.
